The global peptic ulcer drugs market size was valued at USD 4.1  billion in 2021, growing at a significant CAGR of 2.1% from 2022-28. Peptic ulcers are a collection of gastrointestinal illnesses that include gastritis, gastric ulcers, and duodenal ulcers, as well as gastroesophageal reflux disease (GERD) (GERD). Drugs that reduce gastric ulcer secretion, such as PPIs and H2 receptor antagonists, as well as acid neutralisation agents, also including antacids and antibiotics against H. pylori infection, are used to treat peptic ulcers. However, for efficient treatment, these medicines are frequently taken in combination.

View Detailed Report Description at          

Growing prevalence of peptic ulcers, rising adoption of peptic ulcer drugs over surgery, R&D stimulation through government actions, growing number of generic manufacturers of peptic ulcer drugs, changes in disease management, and other factors are driving the global peptic ulcer drugs market. Furthermore, factors such as the rising prevalence of stress-induced ulcers as a result of changing lifestyles and diets, rising smoking rates, and a growing senior population are expected to boost the worldwide peptic ulcer medications market size from 2020 to 2030. Nevertheless, peptic ulcer drug adverse effects, low pipeline productivity, and changes in drug pricing rules are projected to stymie the global peptic ulcer pharmaceuticals market's growth in the future years.

The global peptic ulcer drugs market segmentation:

1) by Product Type: H2 receptor Antagonists, Proton Pump Inhibitors (PPIs), Antacids, Ulcer Protective Drugs, Potassium-Competitive Acid Blockers (P-CAB), Antibiotics, Others.

2) Formulation: Oral tablets, Effervescent Tablets, Effervescent Granules, Syrups, Injections.

3) By Application: Oral tablets, Effervescent Tablets, Effervescent Granules, Syrups, Injections.

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.



The global market for peptic ulcer medications has been controlled by the North American regional segment. The mature healthcare market in the region is essentially driving the regional segment's growth. Research & development activities, in addition to greater spending on the creation of novel and innovative treatments, are driving the expansion of the North American area. Europe is the next major regional sector of the global peptic ulcer medicines market after North America. The presence of prominent competitors in Europe, as well as significant investment on the development of new medications, is one of the main reasons for the market's growth.

Request sample report at                 

There are several industry players working in the Peptic Ulcer Drugs Market, which include Pfizer, Inc. (U.S.) Boehringer Ingelheim GmbH (Germany) Abbott Laboratories (U.S.) Takeda Pharmaceuticals Co. Ltd (Japan) GlaxoSmithKline plc (UK) Yuhan Co. Ltd. (South Korea) AstraZeneca plc (UK) Eisai Co. Ltd. (U.S.) Helicure AB (Sweden) Cadila Healthcare (India)

About Precision Business Insights:

We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.


Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.



Mr. Satya

Precision Business Insights | Toll Free: +1 866 598 1553

Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: | D U N S® Number: 852781747